- Inflexion acquired Rosemont Pharmaceuticals in 2020
- Lucis Pharma is a UK-based specialist pharmaceutical business
- The acquisition will enable Rosemont to enter the unit dose/sachet market
Rosemont Pharmaceuticals, a portfolio company of Inflexion, announced the acquisition of Lucis Pharma, a specialist pharmaceutical business.
Headquartered in Gloucestershire in England, Lucis Pharma is a provider in the development and licensing of novel and exclusive medicines.
The acquisition enables Rosemont, a Leeds-based liquid pharmaceuticals business, to enter the unit dose/sachet market, according to a release.
Inflexion acquired Rosemont in 2020 via its buyout fund.
“As well as continuing to broaden our portfolio and add to our strong growth globally, this acquisition also gives access to pipeline products and developer relationships to accelerate our entry into new product areas such as sachets,” said Howard Taylor, chief executive officer of Rosemont. “We will continue creating innovative solutions that meet the needs of dysphagic patients and establish best practice for their care.”
Inflexion is headquartered in London and has offices in Manchester and Amsterdam. The firm typically invests £10 million to £400 million of equity in each deal.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: 
